Diagnostic Products Aided By HBV Assay Approval; Q3 Index Composite Flat
This article was originally published in The Gray Sheet
Diagnostic Products Corp.'s foray into the U.S. hepatitis B immunoassay market, continued strong Immulite sales and a favorable public policy environment helped push the firm's stock ahead 24.3% in the third quarter
You may also be interested in...
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.